Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).

New drug development in the United States, 1963 through 1984

Mattison, N., Trimble, A. G., & Lasagna, L. C. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.35 · Cited by 53 · see citing works

Drug innovation—what's slowing it down?

Steward, F., & Wibberley, G. (1980) · Nature · doi:10.1038/284118a0 · Cited by 42 · see citing works

The rate of development of new drugs in the United States, 1963 through 1975

Wardell, W. M., Hassar, M., & Anavekar, S. N. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978242133 · Cited by 32 · see citing works

A survey of products licensed in the United Kingdom from 1971‐1981.

Griffin, J. L., & Diggle, G. E. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01251.x · Cited by 27 · see citing works

The Measurement of Pharmaceutical Innovation

Wardell, W. M., & DiRaddo, J. (1980) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1980.tb01660.x · Cited by 21 · see citing works

Pharmaceuticals in seven nations

Chew, R., Smith, G. T., & Wells, N. E. J. (1985) · Monographs · Cited by 18 · see citing works

Trends in the development of new medicines by UK‐owned pharmaceutical companies (1964‐1980).

Prentis, R., & Walker, S. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb05219.x · Cited by 16 · see citing works

A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom.

Speirs, C., & Griffin, J. P. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01545.x · Cited by 15 · see citing works

Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980.

Wardell, W. M., & Le, S. (1983) · PubMed · Cited by 10 · see citing works

The development of self-originated new drugs by Swiss pharmaceutical firms, 1960–1980

Mattison, N., Thomas, E., Trimble, A. G., & Wardell, W. M. (1984) · Regulatory Toxicology and Pharmacology · doi:10.1016/0273-2300(84)90038-2 · Cited by 10 · see citing works

Six months experience of new procedures affecting the conduct of clinical trials in the United Kingdom.

Griffin, J. L., & Stewart, A. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01374.x · Cited by 5 · see citing works

Treatment. A Handbook of Drug Therapy

(1979) · Postgraduate Medical Journal · doi:10.1136/pgmj.55.648.774 · Cited by 3 · see citing works

Fluorine in medicinal chemistry

Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2007) · Chemical Society Reviews · doi:10.1039/b610213c · Cited by 7,616 · see citing works

Concordance of the toxicity of pharmaceuticals in humans and in animals

Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · see citing works

Cyclodextrin-based pharmaceutics: past, present and future

Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 2,002 · see citing works

Prediction of Drug Absorption Using Multivariate Statistics

Egan, W. J., Merz, K. M., & Baldwin, J. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000292e · Cited by 2,015 · see citing works

Cyclodextrins as pharmaceutical solubilizers

Brewster, M. E., & Loftsson, Þ. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.012 · Cited by 1,892 · see citing works

The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data

Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987 · see citing works

Role of Pharmacokinetics and Metabolism in Drug Discovery and Development

Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 713 · see citing works

Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics

Waterbeemd, H. V. D., Smith, D. A., Beaumont, K. C., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 600 · see citing works

A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs

Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 552 · see citing works

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

Ingelman‐Sundberg, M., Oscarson, M., & McLellan, R. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01363-2 · Cited by 539 · see citing works

The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs

Kipp, J. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.07.019 · Cited by 530 · see citing works

Bottom-up approaches for preparing drug nanocrystals: Formulations and factors affecting particle size

Sinha, B., Müller, R. H., & Möschwitzer, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.019 · Cited by 527 · see citing works

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.554 · Cited by 500 · see citing works

High-Throughput Permeability pH Profile and High-Throughput Alkane/Water logPwith Artificial Membranes

Wohnsland, F., & Faller, B. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001020e · Cited by 496 · see citing works

Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations

Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487 · see citing works

A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity

Astashkina, A. I., Mann, B. K., & Grainger, D. W. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.001 · Cited by 432 · see citing works

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 370 · see citing works

Drug research: myths, hype and reality

Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348 · see citing works

High throughput physicochemical profiling for drug discovery

Kerns, E. H. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1134 · Cited by 339 · see citing works

The importance of the domain of applicability in QSAR modeling

Weaver, S., & Gleeson, M. P. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.01.002 · Cited by 339 · see citing works

Amorphous Drug Delivery Systems: Molecular Aspects, Design, and Performance

Kaushal, A. M., Gupta, P., & Bansal, A. K. (2004) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v21.i3.10 · Cited by 311 · see citing works

Preparation and Characterization of Nanofibers Containing Amorphous Drug Dispersions Generated by Electrostatic Spinning

Verreck, G., Chun, I., Peeters, J., Rosenblatt, J., & Brewster, M. E. (2003) · Pharmaceutical Research · doi:10.1023/a:1023450006281 · Cited by 312 · see citing works

Pharmacokinetics

Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309 · see citing works

In silico prediction of drug‐binding strengths to human serum albumin

Colmenarejo, G. (2003) · Medicinal Research Reviews · doi:10.1002/med.10039 · Cited by 292 · see citing works

Pharmaceutical profiling in drug discovery

Kerns, E. H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02649-7 · Cited by 288 · see citing works

Cytochromes P450 as useful biocatalysts: addressing the limitations

O’Reilly, E., Köhler, V., Flitsch, S. L., & Turner, N. J. (2011) · Chemical Communications · doi:10.1039/c0cc03165h · Cited by 279 · see citing works

Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

Lappin, G., & Garner, R. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1037 · Cited by 262 · see citing works

Systemic Availability and Lymphatic Transport of Human Growth Hormone Administered by Subcutaneous Injection

Charman, S. A., Segrave, A. M., Edwards, G. A., & Porter, C. J. H. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200002)89:2 · Cited by 83 · see citing works

Experimental and Computational Screening Models for the Prediction of Intestinal Drug Absorption

Stenberg, P., Norinder, U., Luthman, K., & Artursson, P. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001101a · Cited by 253 · see citing works

ADME/PK as part of a rational approach to drug discovery

Eddershaw, P. J., Beresford, A. P., & Bayliss, M. K. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01540-3 · Cited by 238 · see citing works

Current developments and applications of microfluidic technology toward clinical translation of nanomedicines

Liu, D., Zhang, H., Fontana, F., Hirvonen, J. J., & Santos, H. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.003 · Cited by 238 · see citing works

Prediction of Aqueous Solubility of a Diverse Set of Compounds Using Quantitative Structure−Property Relationships

Cheng, A., & Merz, K. M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020266b · Cited by 237 · see citing works

Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals

Stanton, M. K., & Bak, A. (2008) · Crystal Growth & Design · doi:10.1021/cg800173d · Cited by 239 · see citing works

Applying Mechanisms of Chemical Toxicity to Predict Drug Safety

Guengerich, F. P., & MacDonald, J. S. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600260a · Cited by 230 · see citing works

Comparison of Electrospun and Extruded Soluplus®-Based Solid Dosage Forms of Improved Dissolution

Nagy, Z. K., Balogh, A., Vajna, B., Farkas, A., Patyi, G., Kramarics, Á., & Marosi, G. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22731 · Cited by 223 · see citing works

Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug Metabolism

Baillie, T. A. (2007) · Chemical Research in Toxicology · doi:10.1021/tx7002273 · Cited by 220 · see citing works

Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes

Perrut, M., Jung, J., & Leboeuf, F. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.09.007 · Cited by 215 · see citing works

High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole

Nagy, Z. K., Balogh, A., Démuth, B., Pataki, H., Vígh, T., Szabó, B., Molnár, K., Schmidt, B. T., Horák, P., Marosi, G., et al. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.025 · Cited by 214 · see citing works

Predicting Human Drug Glucuronidation Parameters: Application of In Vitro and In Silico Modeling Approaches

Miners, J. O., Smith, P. A., Sorich, M. J., McKinnon, R. A., & Mackenzie, P. I. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121546 · Cited by 210 · see citing works

Drug permeation in biomembranes

Mälkiä, A., Murtomäki, L. S., Urtti, A. O., & Kontturi, K. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.05.009 · Cited by 188 · see citing works

Pharmaceutical Amorphous Nanoparticles

Jog, R., & Burgess, D. J. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.09.014 · Cited by 186 · see citing works

Toxicogenomics and drug discovery: will new technologies help us produce better drugs?

Ulrich, R. G., & Friend, S. H. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd710 · Cited by 182 · see citing works

The pivotal role of hepatocytes in drug discovery

Soars, M. G., McGinnity, D. F., Grime, K., & Riley, R. J. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.002 · Cited by 172 · see citing works

Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes

McGuckin, M. B., Wang, J., Ghanma, R., Qin, N., Palma, S. D., Donnelly, R. F., & Paredes, A. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.012 · Cited by 171 · see citing works

Prediction of intestinal absorption: comparative assessment of gastroplus™ and idea™

Parrott, N., & Lavé, T. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00132-x · Cited by 170 · see citing works

Biopharmaceutics and pharmacokinetics in drug research

Panchagnula, R. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00344-6 · Cited by 170 · see citing works

Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles

Wais, U., Jackson, A. W., He, T., & Zhang, H. (2015) · Nanoscale · doi:10.1039/c5nr07161e · Cited by 164 · see citing works

Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design

Vandecruys, R., Peeters, J., Verreck, G., & Brewster, M. E. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.006 · Cited by 163 · see citing works

Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations

Lav??, T., Coassolo, P., & Reigner, B. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00003 · Cited by 162 · see citing works

Physiologically-based pharmacokinetic simulation modelling

Grass, G. M., & Sinko, P. J. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00013-3 · Cited by 160 · see citing works

In silico prediction of ADME and pharmacokinetics

Boobis, A. R., Gundert‐Remy, U., Kremers, P. G., Macheras, P. E., & Pelkonen, O. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00185-9 · Cited by 154 · see citing works

Interspecies scaling and comparisons in drug development and toxicokinetics

Ings, R. M. J. (1990) · Xenobiotica · doi:10.3109/00498259009046839 · Cited by 152 · see citing works

Optimization of metabolic stability as a goal of modern drug design

Thompson, T. N. (2001) · Medicinal Research Reviews · doi:10.1002/med.1017 · Cited by 151 · see citing works

Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications

Shih, H.-P., Zhang, X., & Aronov, A. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.194 · Cited by 148 · see citing works

The importance of microfluidics for the preparation of nanoparticles as advanced drug delivery systems

Martins, J. P., Torrieri, G., & Santos, H. A. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1446936 · Cited by 148 · see citing works

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development

Rajman, I., Knapp, L., Morgan, T. M., & Masimirembwa, C. M. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.017 · Cited by 145 · see citing works

Formulation optimization and in situ absorption in rat intestinal tract of quercetin-loaded microemulsion

Gao, Y., Wang, Y., Ma, Y., Yu, A., Cai, F.-H., Shao, W., & Zhai, G. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.03.005 · Cited by 145 · see citing works

Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

Soars, M. G., Grime, K., Sproston, J. L., Webborn, P. J. H., & Riley, R. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014464 · Cited by 144 · see citing works

Graphical Model for Estimating Oral Bioavailability of Drugs in Humans and Other Species from Their Caco-2 Permeability and in Vitro Liver Enzyme Metabolic Stability Rates

Mandagere, A. K., Thompson, T. N., & Hwang, K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010152k · Cited by 140 · see citing works

Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds

Yang, Y., Engkvist, O., Llinàs, A., & Chen, H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201548z · Cited by 139 · see citing works

Applications of Epithelial Cell Culture in Studies of Drug Transport

Tavelin, S., Gråsjö, J., Taipalensuu, J., Ocklind, G., & Artursson, P. (2003) · Humana Press eBooks · doi:10.1385/1-59259-185-x:233 · Cited by 139 · see citing works

Chemoinformatics – predicting the physicochemical properties of 'drug-like' molecules

Blake, J. F. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00062-2 · Cited by 137 · see citing works

Development of a Novel in Vitro Model to Predict Hepatic Clearance Using Fresh, Cryopreserved, and Sandwich-Cultured Hepatocytes

Lau, Y. Y., Sapidou, E., Cui, X., White, R. E., & Cheng, K.-C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1446 · Cited by 132 · see citing works

Transport Characteristics of Fexofenadine in the Caco-2 Cell Model

Petri, N., Tannergren, C., Rungstad, D., & Lennernäs, H. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036913.90332.b1 · Cited by 130 · see citing works

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

Walker, D. K. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02194.x · Cited by 130 · see citing works

Drug Design—Past, Present, Future

Doytchinova, I. A. (2022) · Molecules · doi:10.3390/molecules27051496 · Cited by 121 · see citing works

REDUCTION OFN-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES

Clement, B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120005643 · Cited by 119 · see citing works

In Silico Prediction of Caco‐2 Cell Permeability by a Classification QSAR Approach

Pham‐The, H., González‐Álvarez, I., Bermejo, M., Sanjuan, V. M., Centelles, I., Garrigues, T., & Cabrera‐Pérez, M. Á. (2011) · Molecular Informatics · doi:10.1002/minf.201000118 · Cited by 117 · see citing works

Development of predictive pharmacokinetic simulation models for drug discovery

Norris, D. A., Leesman, G. D., Sinko, P. J., & Grass, G. M. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00232-1 · Cited by 110 · see citing works

High‐throughput screening for stability and inhibitory activity of compounds toward cytochrome P450‐mediated metabolism

Ansede, J. H., & Thakker, D. R. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10545 · Cited by 109 · see citing works

Heterologous Expression and Kinetic Characterization of Human Cytochromes P-450: Validation of a Pharmaceutical Tool for Drug Metabolism Research

Masimirembwa, C. M., Otter, C. A., Berg, M., Jönsson, M., Leidvik, B., Jonsson, E., Johansson, T., Bäckman, A., Edlund, A., & Andersson, T. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15034-9 · Cited by 106 · see citing works

Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding

Wu, J., & Ho, P. C. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.05.002 · Cited by 106 · see citing works

Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges

Basavaraj, S., & Betageri, G. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.003 · Cited by 106 · see citing works

Development of Quantitative Structure−Property Relationship Models for Early ADME Evaluation in Drug Discovery. 2. Blood-Brain Barrier Penetration

Liu, R., Sun, H., & So, S. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010290i · Cited by 104 · see citing works

Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery—Building chiral technology toolboxes

McConnell, O. J., Bach, A., Balibar, C. J., Byrne, N., Cai, Y., Carter, G., Chlenov, M. A., Di, L., Fan, K. Y., Goljer, I., et al. (2007) · Chirality · doi:10.1002/chir.20399 · Cited by 104 · see citing works

Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS

Johnson, K. A., & Plumb, R. S. (2005) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2005.04.048 · Cited by 104 · see citing works

High-throughput screening approaches for investigating drug metabolism and pharmacokinetics

Roberts, S. (2001) · Xenobiotica · doi:10.1080/00498250110060978 · Cited by 104 · see citing works

A High-Capacity LC/MS System for the Bioanalysis of Samples Generated from Plate-Based Metabolic Screening

Janiszewski, J. S., Rogers, K. J., Whalen, K. M., Cole, M. J., Liston, T. E., Duchoslav, E., & Fouda, H. G. (2001) · Analytical Chemistry · doi:10.1021/ac0013251 · Cited by 103 · see citing works

A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats

Willmann, S., Schmitt, W., Keldenich, J., & Dressman, J. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000003373.72652.c0 · Cited by 98 · see citing works

Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents

Rashid, U., Sultana, R., Shaheen, N., Hassan, S. F., Yaqoob, F., Ahmad, M. J., Iftikhar, F., Sultana, N., Asghar, S., Yasinzai, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.022 · Cited by 97 · see citing works

Human embryonic stem cells: Current technologies and emerging industrial applications

Améen, C., Strehl, R., Björquist, P., Lindahl, A. H., Hyllner, J., & Sartipy, P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.012 · Cited by 94 · see citing works

Pharmaceutical applications of cyclodextrins and their derivatives

Dhiman, P., & Bhatia, M. (2020) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-020-01029-3 · Cited by 91 · see citing works

Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies – Development of particle design method

Niwa, T., Miura, S., & Danjo, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.013 · Cited by 90 · see citing works

ADME-Space: a new tool for medicinal chemists to explore ADME properties

Bocci, G., Carosati, E., Vayer, P., Arrault, A., Lozano, S., & Cruciani, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-06692-0 · Cited by 89 · see citing works

QSAR Models for the Prediction of Binding Affinities to Human Serum Albumin Using the Heuristic Method and a Support Vector Machine

Xue, C., Zhang, R., Liu, H., Yao, X., Liu, M., Hu, Z., & Fan, B. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci049820b · Cited by 89 · see citing works

The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery

Smith, N. F., Raynaud, F. I., & Workman, P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0324 · Cited by 79 · see citing works

Application of In Silico, In Vitro and Preclinical Pharmacokinetic Data for the Effective and Efficient Prediction of Human Pharmacokinetics

Grime, K., Barton, P., & McGinnity, D. F. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300476z · Cited by 78 · see citing works

Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling

Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 76 · see citing works

Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone

Khan, T., Ahmad, R., Azad, I., Raza, S., Joshi, S., & Khan, A. R. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.05.008 · Cited by 76 · see citing works

Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing

Combes, R. D., Berridge, T., Connelly, J. C., Eve, M. D., Garner, R. C., Toon, S., & Wilcox, P. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00040-x · Cited by 76 · see citing works

Effect of liquid crystals with cyclodextrin on the bioavailability of a poorly water-soluble compound, diosgenin, after its oral administration to rats

Okawara, M., Hashimoto, F., Todo, H., Sugibayashi, K., & Tokudome, Y. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.06.032 · Cited by 75 · see citing works

Theoretical Predictions of Drug Absorption in Drug Discovery and Development

Stenberg, P., m, C. A. S. B., Luthman, K., & Artursson, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00005 · Cited by 75 · see citing works

Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans

Luttringer, O., Theil, F., Poulin, P., Schmitt‐Hoffmann, A. H., Guentert, T. W., & Lavé, T. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10461 · Cited by 75 · see citing works

The predictivity of the toxicity of pharmaceuticals in humans from animal data — an interim assessment

Olson, H. M., Betton, G. R., Stritar, J. A., & Robinson, D. E. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00261-6 · Cited by 73 · see citing works

Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole

Kumar, S., Shen, J., & Burgess, D. J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.059 · Cited by 71 · see citing works

EVALUATION OF A NOVEL IN VITRO CACO-2 HEPATOCYTE HYBRID SYSTEM FOR PREDICTING IN VIVO ORAL BIOAVAILABILITY

Lau, Y. Y., Chen, Y., Liu, T., Li, C., Cui, X., White, R. E., & Cheng, K. (2004) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)02976-3 · Cited by 71 · see citing works

Bioanalysis in drug discovery and development

Pandey, S., Pandey, P. M., Tiwari, G., & Tıwarı, R. (2010) · Pharmaceutical Methods · doi:10.4103/2229-4708.72223 · Cited by 69 · see citing works

Advanced screening assays to rapidly identify solubility-enhancing formulations: High-throughput, miniaturization and automation

Dai, W., Pollock‐Dove, C., Dong, L. C., & Li, S. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.017 · Cited by 68 · see citing works

Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents

Azad, I., Nasibullah, M., Khan, T., Hassan, F., & Akhter, Y. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.02.013 · Cited by 68 · see citing works

Untitled work

(2004) · PubMed · Cited by 66 · see citing works

Trends in the development of new medicines by UK‐owned pharmaceutical companies (1964‐1980).

Prentis, R., & Walker, S. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb05219.x · Cited by 16 · see citing works

Novel medicines marketed in the UK (1960‐87).

Lis, Y., & Walker, S. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05435.x · Cited by 13 · see citing works

New drug development by United States pharmaceutical firms: With analyses of trends in the acquisition and origin of drug candidates, 1963-1979*

Wardell, W. M., May, M. S., & Trimble, A. G. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.181 · Cited by 20 · see citing works

Development of new drugs originated and acquired by United States–owned pharmaceutical firms, 1963-1976*

Wardell, W. M., DiRaddo, J., & Trimble, A. G. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.160 · Cited by 16 · see citing works

New drug development during and after a period of regulatory change: Clinical research activity of major united states pharmacxeutical firms, 1958 to 1979

May, M. S., Wardell, W. M., & Lasagna, L. C. (1983) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1983.95 · Cited by 12 · see citing works